{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:54:09Z","timestamp":1720745649644},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.3816\/clm.2004.s.006","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:03:18Z","timestamp":1221166998000},"page":"S27-S32","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Ongoing Trials with Yttrium 90\u2013Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma"],"prefix":"10.3816","volume":"5","author":[{"given":"Ivana N.M.","family":"Micallef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2004.s.006_bib1","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2002.02.126","article-title":"Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma","volume":"20","author":"Dillman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.s.006_bib2","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) Bcell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CLM.2004.s.006_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/8.suppl_1.S133","article-title":"Radioimmunotherapy strategies for non-Hodgkin's lymphomas","volume":"8","author":"Corcoran","year":"1997","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2004.s.006_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1634\/theoncologist.5-5-376","article-title":"Monoclonal antibody therapy in lymphoid malignancies","volume":"5","author":"Hainsworth","year":"2003","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2004.s.006_bib5","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.s.006_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0093-7754(03)00237-9","article-title":"Radioimmunotherapy for non-Hodgkin's lymphoma","volume":"30","author":"Emmanouilides","year":"2003","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2004.s.006_bib7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib8","first-page":"831a","article-title":"Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL","volume":"96","author":"Witzig","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.s.006_bib9","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib10","first-page":"92a","article-title":"Reduced-dose Zevalin radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: report of a phase II trial","volume":"94","author":"Witzig","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.s.006_bib11","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.s.006_bib12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.s.006_bib13","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib14","first-page":"407a","article-title":"Yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) induces durable remissions in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): analysis of long-term responders","volume":"102","author":"Witzig","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib15","first-page":"406a","article-title":"A phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non- Hodgkin's lymphoma","volume":"102","author":"Witzig","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.s.006_bib16","first-page":"674a","article-title":"Yttrium-90 Ibritumomab tiuxetan for minimal residual disease in CLL","volume":"102","author":"Liu","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib17","first-page":"408a","volume":"102","author":"Forero-Torres","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.s.006_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.s.006_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib20","first-page":"6a","article-title":"Phase III trial of rituximabchop (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large b-cell lymphoma (DLBCL)","volume":"102","author":"Habermann","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib21","first-page":"408a","article-title":"Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced b-cell follicular NHL in first remission: interim analysis for safety of a multicenter, phase III clinical trial","volume":"102","author":"Radford","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib22","first-page":"406","article-title":"A phase II study of 90yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"102","author":"Younes","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib23","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.s.006_bib24","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue","volume":"16","author":"Liu","year":"1998","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib25","first-page":"248a","volume":"102","author":"Fung","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib26","first-page":"411a","article-title":"Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results","volume":"100","author":"Winter","year":"2002","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib27","first-page":"182a","volume":"100","author":"Nademanee","year":"2002","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib29","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib30","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.s.006_bib31","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2004.s.006_bib32","first-page":"30a","article-title":"Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT)","volume":"102","author":"Vose","year":"2003","journal-title":"Blood"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511701099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511701099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T02:42:36Z","timestamp":1588905756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511701099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":32,"alternative-id":["S1526965511701099"],"URL":"https:\/\/doi.org\/10.3816\/clm.2004.s.006","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}